☰

Huma Mohsin, Ph.D. - Publications

Affiliations: 
2004 University of Missouri - Columbia, Columbia, MO, United States 
Area:
Radiation Chemistry, Pharmaceutical Chemistry, Inorganic Chemistry
Tree Info Similar researchers PubMed Report error

7 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2011 Mohsin H, Jia F, Bryan JN, Sivaguru G, Cutler CS, Ketring AR, Miller WH, Simón J, Frank RK, Theodore LJ, Axworthy DB, Jurisson SS, Lewis MR. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu. Bioconjugate Chemistry. 22: 2444-52. PMID 22053899 DOI: 10.1021/Bc200258X  0.494
2011 Bryan JN, Jia F, Mohsin H, Sivaguru G, Anderson CJ, Miller WH, Henry CJ, Lewis MR. Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy. Cancer Biology & Therapy. 11: 1001-7. PMID 21464612 DOI: 10.4161/Cbt.11.12.15528  0.483
2007 Mohsin H, Fitzsimmons J, Shelton T, Hoffman TJ, Cutler CS, Lewis MR, Athey PS, Gulyas G, Kiefer GE, Frank RK, Simon J, Lever SZ, Jurisson SS. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3. Nuclear Medicine and Biology. 34: 493-502. PMID 17591549 DOI: 10.1016/J.Nucmedbio.2007.03.006  0.494
2006 Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simón J, Frank RK, Jurisson SS, Lewis MR. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu. Bioconjugate Chemistry. 17: 485-92. PMID 16536481 DOI: 10.1021/Bc0502356  0.538
2005 Bryan JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, Lewis MR. Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nuclear Medicine and Biology. 32: 851-8. PMID 16253810 DOI: 10.1016/J.Nucmedbio.2005.05.006  0.493
2004 Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Veterinary and Comparative Oncology. 2: 82-90. PMID 19379188 DOI: 10.1111/J.1476-5810.2004.00041.X  0.452
2004 Bryan JN, Mohsin H, Jia F, Siegall CB, Anderson CJ, Miller WH, Henry CJ, Lewis MR. A two-antibody model for copper-64 radioimmunotherapy: biodistributions and tumor dosimetry in a mouse model of cancer Veterinary and Comparative Oncology. 2: 99-99. DOI: 10.1111/J.1476-5810.2004.0045B.X  0.52
Show low-probability matches.